LitigationUSA
Supreme Court to Weigh Liability of Generic Drug Makers for 'Skinny Label' Patent Infringement in Hikma v. Amarin
On January 16, 2026, the U.S. Supreme Court granted certiorari to review a Federal Circuit ruling in Hikma Pharmaceuticals USA v. Amarin Pharma. The case centers on whether generic drug makers who exclude patented uses from their product labels—so-called 'skinny labels'—can still face patent infringement claims based…
Thursday, May 14, 2026